These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15147030)

  • 1. D2 antagonist augmentation in patients with a partial response to atypical antipsychotics.
    Mazeh D; Melamed Y; Weizman A
    Can J Psychiatry; 2004 Apr; 49(4):281-2. PubMed ID: 15147030
    [No Abstract]   [Full Text] [Related]  

  • 2. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
    Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Grunder G; Carlsson A; Wong DF
    Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Theory in antipsychotic drug therapy for schizophrenia].
    Tomioka S; Ishigooka J
    Seishin Shinkeigaku Zasshi; 2006; 108(6):614-8. PubMed ID: 16910539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
    Kapur S; Zipursky R; Jones C; Remington G; Houle S
    Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine receptor heteromers: biasing antipsychotics.
    Sahlholm K; Valle-León M; Fernández-Dueñas V; Ciruela F
    Future Med Chem; 2018 Dec; 10(23):2675-2677. PubMed ID: 30518245
    [No Abstract]   [Full Text] [Related]  

  • 9. Do atypical antipsychotics really enhance smoking reduction more than typical ones?: the effects of antipsychotics on smoking reduction in patients with schizophrenia.
    Wu BJ; Chen HK; Lee SM
    J Clin Psychopharmacol; 2013 Jun; 33(3):319-28. PubMed ID: 23609378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
    Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies.
    Price R; Salavati B; Graff-Guerrero A; Blumberger DM; Mulsant BH; Daskalakis ZJ; Rajji TK
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():83-91. PubMed ID: 24819820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is an atypical antipsychotic?
    Reynolds GP
    J Psychopharmacol; 1997; 11(3):195-9. PubMed ID: 9305410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
    Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
    J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.